Yf-Vax Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

YF-Vax is a live-attenuated vaccine developed to offer long-term protection against yellow fever, a serious viral illness transmitted by infected mosquitoes. It is frequently recommended for travelers and residents in areas where the disease is endemic.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary forms of YF-Vax include live-attenuated vaccines and fractional dose vaccines. Live-attenuated vaccines consist of weakened, yet live, versions of the virus or bacteria responsible for the disease. The disease can be transmitted through different types: sylvatic yellow fever, intermediate yellow fever, and urban yellow fever. These vaccines are available through multiple distribution channels, such as hospitals, retail pharmacies, and government health programs, and are used by various age groups, including adults, the elderly, and children.

The Yf-Vax market research report is one of a series of new reports from The Business Research Company that provides Yf-Vax market statistics, including Yf-Vax industry global market size, regional shares, competitors with a Yf-Vax market share, detailed Yf-Vax market segments, market trends, and opportunities, and any further data you may need to thrive in the Yf-Vax industry. This Yf-Vax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Yf-Vax market size is expected to see strong growth in the next few years. It will grow to $9,120 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growing demand for vaccination in emerging economies and advancements in vaccine distribution channels, government-sponsored vaccination programs, ongoing advancements in vaccine distribution infrastructure, and improvements in vaccine formulations and availability. Major trends in the forecast period include product approvals, partnerships and developments in yellow vaccine.

The growing awareness of vector-borne diseases is expected to drive the expansion of the yf-vax market. Vector-borne diseases are infectious conditions spread to humans and animals through the bites of infected arthropods, such as mosquitoes, ticks, and fleas, which carry pathogens like viruses, bacteria, or parasites, leading to illnesses such as malaria, dengue, and Lyme disease. The rise in the prevalence of these diseases is attributed to factors like climate change, urbanization, increased global travel, and the expansion of mosquito populations, resulting in more frequent outbreaks. YF-Vax helps prevent yellow fever, a vector-borne disease, by stimulating the immune system to produce antibodies that provide long-lasting protection against the virus spread by infected mosquitoes. For example, in March 2024, the World Organization for Animal Health reported 2,422 outbreaks of vector-borne diseases across 28 countries from 2023 to March 2024, with Europe experiencing 697 outbreaks. As awareness of vector-borne diseases rises, it is contributing to the growth of the yf-vax market.

The increasing healthcare spending is expected to drive the yf-vax market's growth. Factors such as an aging population, advancements in medical technology, the growing prevalence of chronic diseases, and higher demand for healthcare services are contributing to rising healthcare expenditures. YF-VAX helps reduce healthcare costs by preventing severe yellow fever infections, which lowers expenses associated with treatment, hospitalizations, and outbreak management. For instance, in May 2024, the Office for National Statistics in the UK reported that healthcare spending grew by 5.6% from 2022 to 2023, compared to 0.9% growth in 2022. The UK's healthcare expenditure amounted to $317.63 billion (£292 billion) in 2023. Consequently, the rise in healthcare spending is fostering the growth of the yf-vax market.

A notable trend in the yf-vax market is the adoption of strategic partnerships to enhance technological integration and expand market presence. Strategic partnerships involve collaborations between organizations, where they combine resources, expertise, and efforts to achieve mutual goals. For example, in March 2022, the International Finance Corporation (IFC), a US-based financial services company, partnered with Institut Pasteur de Dakar (IPD), a Senegal-based yellow fever vaccine manufacturer, to establish a vaccine manufacturing facility in Senegal. The $222 million project, financed through a combination of public, private, and grant funding, will significantly boost IPD's production capacity, initially focusing on COVID-19 vaccines, with plans to expand to other vaccines. Once fully operational, the facility aims to produce up to 300 million doses annually for Africa.

Major players operating in the yf-vax market are Sanofi S.A

North America was the largest region in the yf-vax market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in yf-vax report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the yf-vax market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The yf-vax market consists of sales of vaccine syringes, pre-filled injection devices, and immunization kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Yf-Vax Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on yf-vax market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for yf-vax ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The yf-vax market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Live Attenuated Vaccines; Fractional Dose Vaccine
• 2) By Transmission Type: Sylvatic Yellow Fever; Intermediate Yellow Fever; Urban Yellow Fever
• 3) By Distribution Channel: Hospitals; Retail Pharmacies; Government Health Programs
• 4) By End User: Adult; Geriatric; Pediatric
• Companies Mentioned: Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.